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Okaramines produced by Penicillium simplicissimum AK-40 activate 
L-glutamate-gated chloride channels (GluCls) and thus paralyze insects. 
However, the okaramine binding site on insect GluCls is poorly 
understood. Sequence alignment shows that the equivalent of residue 
Leucine319 of the okaramine B sensitive Bombyx mori GluCl is a 
phenylalanine in the okaramine B insensitive B. mori γ-aminobutyric 
acid-gated chloride channel (BmGABACl) of the same species. This 
residue is located in the third transmembrane (TM3) region, a location 
which in a nematode GluCl is close to the ivermectin binding site. The B. 
mori GluCl containing the L319F mutation retained its sensitivity to 
L-glutamate, but responses to ivermectin were reduced and those to 
okaramine B were completely blocked.  
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Fungi produce diverse secondary metabolites in response to environmental 
changes [1, 2]. An intriguing example is the production by fungi of insect 
regulating metabolites in the soybean pulp “okara”. In 1989, Penicillium 
simplicissimum AK-40 cultured on okara was found to produce the indole 
alkaloids okaramines A and B (Fig. 1A), compounds showing insecticidal activity 
on the silkworm larvae of Bombyx mori [3]. Both okaramines possess a novel 
skeleton featuring the eight-membered azocine ring, and the pioneering studies 
inspired the total synthesis of okaramine N by Baran et al. at Harvard University 
[4]. Further exploration of insect-active fungal metabolites led to the isolation of 
insecticidal meroterpenoids, cyclic peptides as well as the other alkaloids [5]. 
Although successive discoveries of insect-modulating fungal metabolites 
were reported, their sites of action remained elusive, triggering investigations on 
possible targets. When tested on silkworm larvae, uncoordinated motility was 
rapidly observed, followed by paralysis or death, indicating that such compounds 
may modulate neural transmission [5]. Whole-cell patch-clamp electrophysiology 
was employed to show that whereas asperparaline A [6] and chrodrimanins [7] 
blocked the acetylcholine- and γ-aminobutyric acid (GABA)-induced currents, 
respectively, okaramines induced chloride currents in neurons [8]. In particular, 
okaramines activated B. mori L-glutamate-gated chloride channels (BmGluCls), 
while having no effect on B. mori GABA-gated chloride channels (BmGABACls). 
The order of their GluCl activating potency (okaramine B > 
4,5’-dihydrookaramine B > okaramine A > okaramine Q) correlated with their 
insecticidal potency, thereby supporting the view that the primary target of 
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okaramines is GluCl [8].  
To explore further the site of action of okaramine B, we tested its capacity to 
displace the specific binding of [3H]ivermectin to membranes prepared from 
HEK293 cells expressing the exon 3c variant of BmGluCl. Okaramine B 
displaced [3H]ivermectin binding in a non-competitive fashion in that Bmax was 
reduced whereas Kd was unaffected, pointing to the possibility of a distinct site 
of binding from that of ivermectin [9]. However, this hypothesis requires further 
testing, because both classes of compounds activate GluCl, inducing persistent 
chloride currents in oocytes expressing BmGluCl.  
In the crystal structure of the C. elegans GluCl α-subunit in complex with 
ivermectin [10], glycine342 and methionine345 in the third transmembrane 
region (TM3) (Fig. 1B) are located closest to ivermectin (Fig. 1C). Of these two 
amino acids, the glycine342 in the C. elegans GluCl is preserved in insect 
GluCls and GABACls, whereas the equivalent of methionine345 is leucine319 in 
the okaramine B-sensitive BmGluCl and phenylalanine319 in the okaramine 
B-insensitive B. mori GABA-gated chloride channel (BmGABACl) (Fig. 1B). 
Therefore, we investigated the effects of the L319F mutation in BmGluCl on the 
GluCl-activating action of okaramine B. 
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Materials and Methods 
Chemicals 
Okaramine B was isolated from the P. simplicissimum AK-40 metabolites 
generated when the fungus was grown on okara [3]. Ivermectin and sodium 
L-glutamate were purchased from Merck/Sigma-Aldrich (St. Louis, MO, USA) 
and Wako Pure Chemical Industries (Osaka, Japan), respectively.  
 
cRNA preparation and injection to Xenopus oocytes 
The exon 3c variant of BmGluCl (accession number; KC342245) [11] was 
employed to investigate the actions of compounds in terms of inducing inward 
currents in oocytes expressing the BmGluCls, since the current amplitude of its 
response to L-glutamate and ivermectin is largest among all the splice variants 
[11]. The cDNA was cloned into the pcDNA3.1 (+) vector (Thermo Fisher 
Scientific) and the nucleotide was mutated by polymerase chain reaction. Wild 
type and mutant cDNAs were linearized by cutting the 3’ end with BamHI and 
cRNA was prepared with the linearized cDNA using the mMESSAGE 
mMACHINE Ultra T7 kit (Thermo Fisher Scientific) as previously described [11].  
Oocytes were isolated from female Xenopus laevis anesthetized according 
to the according to the U.K. Animals Act, 1986 and the follicle membranes were 
removed from oocytes after collagenase treatment [12, 13, 14]. Each oocyte was 
injected with 50 ng of cRNA and incubated in Standard Oocyte Saline (SOS) 
containing 100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, and 5 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.6) supplemented with 
antibiotics [penicillin (100 units ml1), streptomycin (100 μg ml1), gentamycin (20 
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μg ml1)] and 2.5 mM sodium pyruvate for 24 h prior to recording GluCl response 
by two-electrode voltage-clamp electrophysiology. 
 
Two-electrode voltage-clamp electrophysiology  
Oocytes were perfused extracellularly at a flow rate of 7-10 ml min-1 [12, 13, 
14]. The transmembrane currents of oocytes were recorded using 3MKCl-filled 
glass microelectrodes (Resistance 0.5–5 MΩ) coupled to a GeneClamp 500B 
amplifier using Clampex 8 software (Molecular Devices, Sunnyvale, CA, USA). 
The currents were digitized using a Digidata1200 A/D converter (Molecular 
Devices) and analyzed using Clampfit 9 software (Molecular Devices). Oocytes 
were clamped at a holding potential (Eh) = -80 mV. The peak current amplitude 
of the response to each ligand was normalized to the peak current amplitude of 
the response to 100 μM L-glutamate. The concentration-normalized response 
data were fitted by non-linear regression with Prism 5 (GraphPad, CA, USA) 
according to the equation (1). 
Y = Imax/(1+10(logEC50-X)nH)  (1) 
In equation (1), X is log[ligand concentration (M)], Imax is maximal normalized 
response, EC50 is half-maximal concentration and nH is the Hill coefficient. The 
Imax and pEC50 values for each ligand were obtained by repeated experiments 




L-glutamate concentration-response curves for wild type BmGluCl and the 
L319F mutant 
When bath-applied alone, L-glutamate resulted in concentration-dependent, 
inward currents at Eh –80 mV in oocytes expressing either wild type or L319F 
mutant BmGluCl (Fig. 2). In the case of wild type BmGluCl, the 
concentration-response curve for L-glutamate reached a maximum at 100 μM 
with a pEC value of 3.61 ± 0.20 (Fig. 2B, Table 1). The L319F mutation did not 
significantly affect the pEC50 value of L-glutamate (3.54 ± 0.07) (Table 1). 
 
Actions of ivermectin on wild type BmGluCl and the L319F mutant 
It is well documented that ivermectin primarily targets GluCls, although it has 
some modulatory actions on GABACls and related ligand-gated ion channels 
[15]. Ivermectin induced inward currents in Xenopus oocytes expressing wild 
type and L319F mutant BmGluCl, with rise and decay times slower than those 
observed for L-glutamate-induced currents (Fig. 3A). At micromolar 
concentrations, such ivermectin actions were irreversible and thus a single 
oocyte was used to record only one ivermectin-induced response at each 
concentration. Using this protocol, the pEC50 and Imax values of ivermectin for 
the wild type GluCl were determined to be 6.23 ± 0.09 and 0.24 ± 0.02, 
respectively (Fig. 3B). The L319F mutation slowed desensitization of the 
ivermectin-induced response (Fig. 3A) and shifted both pEC50 and Imax values 




Actions of okaramine B on wild type BmGluCl and the L319F mutant 
Okaramine B was bath-applied to oocytes expressing the wild type and 
L319F mutant BmGluCl; it activated the wild type BmGluCl, inducing the inward 
currents which were concentration-dependent (Fig. 4A, B) with pEC50 and Imax 
values of 6.25 ± 0.10 and 0.19 ± 0.01, respectively (Table 1). However, the 
compound was completely ineffective when tested on oocytes expressing the 
L319F mutant (Fig. 4A, B) at concentrations from 10 nM to100 μM. Thus, a 
pEC50 value could not be determined.  
 
Effect of co-application of okaramine B on the L-glutamate-induced 
response of the L319F mutant of BmGluCl. 
As shown in Fig. 4, okaramine B was incapable of activating the L319F 
mutant of BmGluCl. However, it could potentially act as antagonist or allosteric 
modulator on the mutant. Hence, okaramine B was applied at 10 μM for 1 min 
and then co-applied with 100 μM L-glutamate. This resulted in a 31% reduction 
of the peak current amplitude of the L-glutamate response (Figure 5, n = 4). 
 
Discussion 
In this work, we have for the first time investigated the effects of the L319F 
mutation in TM3 of larval silkworm (B. mori) GluCl on the receptor’s sensitivity to 
L-glutamate, okaramine B and ivermectin. Based on structural studies on the C. 
elegans GluCl with ivermectin bound [10], the residue equivalent to the one 
investigated here is likely also involved in the formation of the allosteric site. 
Thus, not surprisingly perhaps, the L319F mutation had no significant effect on 
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the concentration-response curve of L-glutamate. The C. elegans studies of 
GluCl with L-glutamate bound showed binding of the natural ligand with the 
orthosteric site [10]. In contrast, the L319F mutation reduced the response to 
both ivermectin and okaramine B. The more profound effect was observed on 
the actions of okaramine B, the response to which was obliterated over the 
concentration range 10 nM to 100 µM. The response to ivermectin was 
considerably reduced but concentration-dependent responses were still 
detected in the range 300 nM – 30 µM. One plausible interpretation of this result 
is that okaramine B and ivermectin partly share a common allosteric binding site 
on BmGluCl but that bound okaramine B is located closer to leucine319 than is 
the case for bound ivermectin. Our previous observation that okaramine B 
displaced the binding of [3H] ivermectin to the membrane fractions containing 
BmGluCl in a non-competitive fashion [9] may be reconciled if the binding of 
okaramine B to one of five allosteric sites on BmGluCl attenuates the binding of 
ivermectin to the remaining four allosteric sites. To examine whether this is the 
case, it will be necessary to solve the X-ray crystal structure of an insect GluCl in 
complex with okaramine B.  
The complete block of an activating response to okaramine B in the L319F 
mutant allowed us to address any possible modification (enhancement or block) 
by okaramine B of the response to L-glutamate. We detected a small but 
significant antagonist action in the L319F mutant. This suggests that whereas in 
the wild type BmGluCl occupation of the okaramine B binding site allows 
unimpaired coupling between the orthosteric binding site movement and channel 
opening, in the L319F mutant okaramine B can still bind but coupling between 
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orthosteric site movement and channel opening in response to L-glutamate is 
attenuated. It should also be noted that the reduction by okaramine B of the peak 
response to L-glutamate of the L319F mutant of BmGluCl was only 31%, a not 
strong effect.  
Since the L319F mutation hardly affects the response to L-glutamate, this 
may facilitate the generation of viable GluCl mutants of insects that are 
okaramine B- and ivermectin-resistant. Such mutants would be valuable in 
counter screens of small molecule mimics of okaramine B in the search for new 
insecticide leads. Our findings also suggest that it will be important to remain 
alert for the detection of resistance due to mutations in the equivalent residue to 
B. mori leucine319 in pest lepidoptera and other insect and acarine species 
exposed to abamectin and ivermectin. We have in the past pointed to the 
possibility of resistance emerging from mutations in loop D of the nicotinic 
acetylcholine receptor, which impact on neonicotinoids but not acetylcholine [13] 
and later such mutations were found in field populations [16].   
In conclusion, we have shown that a novel L319F mutation in TM3 of 
BmGluCl reduced okaramine B sensitivity more profoundly than its impact on 
ivermectin sensitivity, indicative of okaramine B interactions with GluCl in the 
vicinity of leicine319. In spite of these differences in their actions and the 
non-competitive actions of okaramine B in the displacement of [3H]ivermectin 
binding to the membrane fractions prepared from H293 cells expressing 
BmGluCl, further studies, in particular structural studies, will be needed to 
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Table 1. pEC50 and Imax values1 for L-glutamate, ivermectin and okaramine B 
actions on wild type and L319F mutant BmGluCl of the larval silkworm Bombyx 
mori expressed in Xenopus laevis oocytes 
Compounds Wild type  L319F Mutant  
 pEC50 Imax pEC50 Imax 
L-Glutamate 3.61 ± 0.20 1.37 ± 0.12 3.54 ± 0.07 1.13 ± 0.05 
Ivermectin 6.23 ± 0.09 0.24 ± 0.02 5.11 ± 0.71 0.08 ± 0.05 
Okaramine B 6.25 ± 0.10 0.19 ± 0.01 ND2 ND 
1 Data are represented as mean ± standard error of the mean (n = 4). 
2Could not be determined because okaramine B was inactive in the range 




Figure 1. Structures of ivermectin B1a and okaramine B (A) and the alignment 
of amino acid sequences of C. elegans and insect GluCls and insect 
GABA-gated chloride channels (GABACls) (B). Accession numbers of protein 
sequences compared: C. elegans GluCl, AAA50785.1; B. mori GluCl, 
BAD16657.1; Drosophila melanogaster GluCl, AAG40735.1; M. domestica 
GluCl AGW27406.1; Anopheles gambiae GluCl, AGS43092.1; B. mori GABACl, 
BAN92442.1; D. melanogaster GABACl, AAA28556.1; M. domestica GABACl, 
BAD16658.2; A. gambiae GABACl, APA16887.1. Amino acid sequences are 
numbered according to the Bombyx GluCl when counted from the start 
methionine1. The position of leucine319 of BmGluCl (=methionine345 of C. 
elegans GluCl) is indicated by an arrow. (C) The crystal structure of the C. 
elegans GluCl with ivermectin bound (3RHW). The figures were generated 
using PyMOL software. Methionine345 corresponding to leucine319 of 
BmGluCl and phenylalanine319 of BmGABACl is indicated by space filling 
model where carbons, oxygen, nitrogen and sulfur are colored white, red, blue 
and yellow, respectively. Ivermectin is shown as a wire model where carbons 
and oxygens are colored green and red, respectively.    
 
Figure 2. Effects of the BmGluCl L319F mutation on the response to L-glutamate. 
(A) Inward currents induced by L-glutamate in Xenopus laevis oocytes 
expressing the wild type and L319F mutant GluCl. (B) Concentration-response 
curve of L-glutamate for the wild type and L319F mutant GluCl. Data are 
represented as mean ± standard error (n = 4). 
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Figure 3. Effects of the BmGluCl L319F mutation on the response to ivermectin. 
(A) Inward currents evoked by ivermectin in Xenopus laevis oocytes expressing 
the wild type and L319F mutant of BmGluCl. The application of ivermectin is 
indicated by horizontal lines. (B) Concentration-response curve of ivermectin for 
the wild type and L319F mutant BmGluCl. Data are represented as mean ± 
standard error (n = 4). 
 
Figure 4. Effects of the BmGluCl L319F mutation on the response to okaramine 
B. (A) Inward currents evoked by okaramine B in Xenopus laevis oocytes 
expressing the wild type and L319F mutant BmGluCl. Application of okaramine 
B is indicated by horizontal lines. (B) Concentration-response curve of 
okaramine B for the wild type and L319F mutant BmGluCl. Data are represented 
as mean ± standard error (n = 4).  
 
Figure 5. Effects of co-application of okaramine B on the response to 
L-glutamate of BmGluCl expressed in Xenopus laevis oocytes. (A) After 
recording a control response to 100 μM L-glutamate, 10 μM okaramine B was 
bath-applied at 10µM for 1 min and then co-applied with 100 μM L-glutamate for 
2 s to an oocyte expressing BmGluCl. After washing for 3 min with SOS, 100 μM 
L-glutamate was applied again. Application of L-glutamate and okaramine B are 
indicated by solid and hashed horizontal lines, respectively. (B) Effects of 10 μM 
okaramine B on the peak amplitude of the response to 100 μM L-glutamate of 
BmGluCl. The data represent mean ± standard error of the mean (n = 4). *, 
Difference is statistically significant by paired t test (P<0.05). 
